TNFRSF1B and primary cutaneous T-cell non-Hodgkin lymphoma: Due to the role of this receptor, TNFR2 antagonism has been suggested as a new promising strategy in cancer immunotherapy specifically in ovarian, lung, and cutaneous T cell lymphoma (112, 113).